V
Vir Biotechnology, Inc. (VIR)
NMS – Real vaqt narxi. Valyuta: USD
9.40
+0.11 (1.18%)
Yopilishda: May 12, 2026, 4:00 PM EDT
9.45
+0.05 (0.53%)
Bozor oldidan: May 13, 2026, 4:00 AM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
9.40
+0.11 (1.18%)
Yopilishda: May 12, 2026, 4:00 PM EDT
9.45
+0.05 (0.53%)
Bozor oldidan: May 13, 2026, 4:00 AM EDT
Vir Biotechnology, Inc., klinik bosqichdagi biofarmatsevtika kompaniyasi, Qo'shma Shtatlar va xalqaro miqyosda jiddiy yuqumli kasalliklarni davolash va oldini olish uchun terapevtik mahsulotlarni kashf qiladi va ishlab chiqadi. Uning klinik rivojlanish quvuri gepatit delta virusi (HDV) va boshqa qattiq o'smalarga qaratilgan mahsulot tadqiqot terapiyalaridan iborat. Kompaniyaning preklinik nomzodlari orasida gripp A va B viruslariga qarshi antitelalar va antitelali dori kon'yugatlarini hamda koronavirusga qarshi monoklonal antitelalarni maqsad qiluvchi preparatlar mavjud; va PRO-XTEN, turli qattiq o'smalarga qaratilgan er-xotin niqoblangan TCElar. Kompaniyaning Astellas bilan grant hamkorligi va litsenziya shartnomasi; CHDni davolash uchun Norgine bilan litsenziya shartnomasi; Geyts jamg'armasi bilan o'zgartirilgan va qayta ko'rib chiqilgan xat kelishuvi; Brii Biosciences Limited bilan opsion va litsenziya shartnomasi; Alnylam Pharmaceuticals, Inc. bilan hamkorlik va litsenziya shartnomasi; Biotibbiyot tadqiqot instituti bilan litsenziya shartnomasi; Rokfeller universiteti bilan litsenziya shartnomasi; Xencor bilan litsenziya shartnomalari; va GlaxoSmithKline Biologicals S.A. bilan hamkorlikdagi tadqiqot shartnomasi mavjud. Vir Biotechnology, Inc. 2016 yilda tashkil etilgan va uning shtab-kvartirasi San-Frantsisko, Kaliforniyada joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Jennifer Eileen Towne Ph.D. | Executive VP & Chief Scientific Officer |
| Dr. Kiki Patel Pharm.D. | Head of Investor Relations |
| Dr. Lawrence Corey M.D. | Co-Founder & Scientific Advisor |
| Dr. Louis J. Picker M.D. | Co-Founder & Scientific Advisor |
| Dr. Maninder Hora Ph.D. | Executive VP & Chief Technical Operations Officer |
| Dr. Marianne De Backer M.B.A., M.Sc., Ph.D. |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-07 | 10-Q | vir-20260331.htm |
| 2026-05-06 | 8-K | vir-20260506.htm |
| 2026-04-16 | DEFA14A | a2026defa14aproxymaterials.htm |
| 2026-04-16 | ARS | ef20070778_ars.pdf |
| 2026-04-10 | 8-K | d121549d8k.htm |
| 2026-03-04 | 8-K | d88412d8k.htm |
| 2026-03-02 | 8-K | d50465d8k.htm |
| 2026-02-26 | 8-K | d85338d8k.htm |
| 2026-02-23 | S-8 | a20260223forms-8.htm |
| 2026-01-12 | 8-K | vir-20260112.htm |
| President, CEO & Director |
| Mr. Brent Sabatini | Senior VP, Principal Accounting Officer & Chief Accounting Officer |
| Mr. Jason O'Byrne M.B.A. | Executive VP & CFO |
| Ms. Carolyn Wang | Senior Vice President of Corporate Communications |
| Ms. Vanina de Verneuil J.D. | Executive VP, General Counsel & Corporate Secretary |